

Curriculum vitae

General information

Name	Weske, Sarah , Dr. rer. nat.
Date of birth	03.03.1986, Essen, female
Work address	Institute for Molecular Biology III Heinrich Heine University Düsseldorf Moorenstr. 5 D-40225 Düsseldorf
Phone:	+49-(0) 211-81- 8110466
Email:	sarah.weske@med.uni-duesseldorf.de
Current position	Post-Doctoral fellow of the Institute for Molecular Medicine III, Medical Faculty, University Hospital, Heinrich Heine University Düsseldorf
Children	One child, years of birth 2021 Periods of parental leave: May 2021 – February 2022

University training and degree

Add. qualification	2010, Master of Science of Medical Biology, University Duisburg-Essen 2008, Bachelor of Science of Medical Biology, University Duisburg-Essen
Subjects of study	2005-2010, Study of Medical Biology, University Duisburg-Essen

Advanced academic qualifications

Doctorate	2017, Institute for Pathophysiology, Medical Faculty, University Hospital Essen, University Duisburg-Essen
-----------	---

Postgraduate professional career

since 2020	Post-Doctoral fellow of the Institute for Molecular Medicine III, Medical Faculty, University Hospital, Heinrich Heine University Düsseldorf, Prof. Dr. Bodo Levkau
2017– 2019	Post-Doctoral fellow, Institute for Pathophysiology, Medical Faculty, University Hospital Essen, University Duisburg-Essen, Prof. Dr. Bodo Levkau
2010 –2017	Graduate student, Institute for Pathophysiology, Medical Faculty, University Hospital Essen, University Duisburg-Essen, Prof. Dr. Bodo Levkau

Publications

1. Polzin A, Dannenberg L, Schroeder N, Benkhoff M, Vogt J, Keul P, Weske S, Sarabhai T, Zeus T, Mueller T, Wolnitzke P, Graele M, Roden M, Kelm M and Levkau B. Impaired Cardioprotection by HDL in CAD and Diabetes in Ischemia/Reperfusion Injury: role of S1P and SR-BI. *Eur Heart J.* 2022;43:2913-2913.
2. Polzin A, Dannenberg L, Benkhoff M, Barcik M, Keul P, Ayhan A, Weske S, Ahlbrecht S, Trojovský K, Helten C, Haberkorn S, Floegel U, Zeus T, Müller T, Graler MH, Kelm M and Levkau B. Sphingosine-1-phosphate improves outcome of no-reflow acute myocardial infarction via sphingosine-1-phosphate receptor 1. *Esc Heart Fail.* 2022.
3. Polzin A, Dannenberg L, Benckhoff M, Barcik M, Keul P, Weske S, Ahlbrecht S, Helten C, Haberkorn S, Floegel U, Zeus T, Mueller T, Graeler M, Kelm M and Levkau B. S1P lyase inhibition improves post-ischemic cardiac remodeling independently of infarct size via S1P receptor 1. *Eur Heart J.* 2022;43:2912-2912.
4. Keul P, Peters S, von Wnuck Lipinski K, Schroder NH, Nowak MK, Duse DA, Polzin A, Weske S, Graler MH and Levkau B. Sphingosine-1-Phosphate (S1P) Lyase Inhibition Aggravates Atherosclerosis and Induces Plaque Rupture in ApoE(-/-)Mice. *Int J Mol Sci.* 2022;23.
5. Dannenberg L, Weske S, Kelm M, Levkau B and Polzin A. Cellular mechanisms and recommended drug-based therapeutic options in diabetic cardiomyopathy. *Pharmacol Therapeut.* 2021;228.
6. Weske S, Vaidya M, Lipinski KV, Keul P, Manthe K, Burkhart C, Haberhauer G, Heusch G and Levkau B. Agonist-induced activation of the S1P receptor 2 constitutes a novel osteoanabolic therapy for the treatment of osteoporosis in mice. *Bone.* 2019;125:1-7.
7. Vaidya M, Jentsch JA, Peters S, Keul P, Weske S, Graler MH, Mladenov E, Iliakis G, Heusch G and Levkau B. Regulation of ABCA1-mediated cholesterol efflux by sphingosine-1-phosphate signaling in macrophages. *J Lipid Res.* 2019;60:506-515.
8. Weske S, Vaidya M, Reese A, Lipinski KV, Keul P, Bayer JK, Fischer JW, Floegel U, Nelsen J, Epple M, Scatena M, Schwedhelm E, Dorr M, Volzke H, Moritz E, Hannemann A, Rauch BH, Graler MH, Heusch G and Levkau B. Targeting sphingosine-1-phosphate lyase as an anabolic therapy for bone loss. *Nat Med.* 2018;24:667-+.
9. Lipinski KV, Weske S, Keul P, Peters S, Baba HA, Heusch G, Graler MH and Levkau B. Hepatocyte nuclear factor 1A deficiency causes hemolytic anemia in mice by altering erythrocyte sphingolipid homeostasis. *Blood.* 2017;130:2786-2798.

10. Lipinski KV, Sattler K, Peters S, Weske S, Keul P, Klump H, Heusch G, Gothert JR and Levkau B. Hepatocyte Nuclear Factor 1A Is a Cell-Intrinsic Transcription Factor Required for B Cell Differentiation and Development in Mice. *J Immunol.* 2016;196:1655-1665.

11. Sattler K, Graler M, Keul P, Weske S, Reimann CM, Jindrova H, Kleinbongard P, Sabbadini R, Brocker-Preuss M, Erbel R, Heusch G and Levkau B. Defects of High-Density Lipoproteins in Coronary Artery Disease Caused by Low Sphingosine-1-Phosphate Content Correction by Sphingosine-1-Phosphate-Loading. *J Am Coll Cardiol.* 2015;66:1470-1485.

12. Nussbaum C, Bannenberg S, Keul P, Graler MH, Goncalves-de-Albuquerque CF, Korhonen H, Lipinski KV, Heusch G, Neto HCDF, Rohwedder I, Gothert JR, Prasad VP, Haufe G, Lange-Sperandio B, Offermanns S, Sperandio M and Levkau B. Sphingosine-1-phosphate receptor 3 promotes leukocyte rolling by mobilizing endothelial P-selectin. *Nat Commun.* 2015;6.

13. Brautigam L, Jensen LDE, Poschmann G, Nystrom S, Bannenberg S, Dreij K, Lepka K, Prozorovski T, Montano SJ, Aktas O, Uhlen P, Stuhler K, Cao YH, Holmgren A and Berndt C. Glutaredoxin regulates vascular development by reversible glutathionylation of sirtuin 1. *P Natl Acad Sci USA.* 2013;110:20057-20062.

14. Berndt C, Kurz T, Bannenberg S, Jacob R, Holmgren A and Brunk UT. Ascorbate and endocytosed Motexafin gadolinium induce lysosomal rupture. *Cancer Lett.* 2011;307:119-123.